Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnylam Pharmaceuticals has received notice of allowance (NoA) from US Patent and Trademark Office (USPTO) for new patent covering second generation lipid nanoparticle (LNP) platform, including the MC3 lipid.
Subscribe to our email newsletter
The patent application includes 30 claims covering composition of matter and formulations of MC3, as well as methods of using these compositions and formulations.
This second generation LNP delivery platform is being utilized in development programs as part of the company’s Alnylam 5×15 product strategy.
The LNP delivery platform is used in ALN-TTR02, for the treatment of transthyretin-mediated amyloidosis (ATTR); ALN-PCS, for the treatment of severe hypercholesterolemia; and potentially other programs.
Alnylam senior vice president and chief business officer Laurence Reid said LNPs exhibit significant improvements in potency and therapeutic index for RNAi therapeutics, as evidenced by human data with ALN-PCS.
"These novel LNPs also define Alnylam’s LNP platform for advancement of ALN-TTR02 and potentially other ‘Alnylam 5×15’ programs," Reid added.